相关实验视频

Updated: Jan 26, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

可吸入的隐形脂质体改善了用于肺纤维化治疗的递送

Ruibo Lin¹, Zhengqing Li², Yuelan Sun³

¹School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.

Journal of controlled release : official journal of the Controlled Release Society

|January 24, 2026

概括

研究人员开发了一种新的脂质体系统,以改善吸入CSP7的传递,这是一种用于治疗肺纤维化的药物. 这种纳米载体增强了药物向肺组织的作用,在动物模型中显示出有前途的治疗效果.

科学领域:

肺部医学肺部医学
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

肺纤维化是一种严重的肺部疾病,治疗选择很少.
体CSP7显示出抗纤维素的潜力,但在纤维化肺部面临着传递挑战.
障碍物包括膜水和巨细胞清除,阻碍有效的CSP7吸入.

研究的目的:

开发一个脂质体纳米载体系统,通过吸入增强CSP7的肺部输送.
克服纤维化肺部的生理障碍,以提高治疗疗效.
在临床前模型中评估新型配方的抗纤维素作用.

主要方法:

为了更好的脂质体结合,CSP7被修改为脂质原药 (l-CSP7).
基化隐形脂质体 (l-CSP7/Lips) 的配方是为了增强药物负载和稳定性.
在体外研究中评估了通过液的透和巨细胞相互作用.
在体内研究中,动物使用了白素和二氧化诱导的肺纤维化模型.

主要成果:

在l-CSP7/Lips配方中,封装效率和药物负载增加了4倍.
脂质体显示出膜水液的透率有所改善,并减少了巨细胞吸收.
在动物模型中,吸入l-CSP7/Lips显著逆转了肺纤维化重塑和改善了呼吸功能.
与自由的CSP7和nintedanib相比,治疗减少了炎症和原沉积.

结论:

一个高负载的隐形脂肪体系统有效地通过吸入增强了CSP7的肺输送.
这种纳米载体平台为肺纤维化局部治疗提供了一个有希望的策略.
这些发现支持了使用先进的纳米载体系统治疗肺部疾病的可吸入疗法的潜力.

关键词:

在CSP7中,吸入的管理方式是吸入.脂质细胞体中的脂肪体.的交付的交付.肺部纤维化肺部纤维化

更多相关视频

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

相关概念视频

Pulmonary Ventilation: Inhalation

Pulmonary Ventilation: Inhalation

Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...

Inhaled Medications

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Peptide Bonds

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...